MedPath

Hyaluronic acid

Generic Name
Hyaluronic acid
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C28H44N2O23
CAS Number
9004-61-9
Unique Ingredient Identifier
S270N0TRQY
Background

Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan found in connective, epithelial, and neural tissues; it was first isolated in 1934. Karl Meyer and John Palmer obtained glycosaminoglycan (GAG) from the bovine eye, giving it the name “hyaluronic acid”. HA is involved in many important physiological processes, including but not limited to wound healing, tissue regeneration, and joint lubrication. It demonstrates unique viscoelasticity, moisturizing, anti-inflammatory qualities, and other important properties that prove beneficial in various clinical applications.

HA is used in drug delivery systems for the treatment of cancer, ophthalmological conditions, joint conditions, and aesthetic imperfections. Several preparations of hyaluronic acid have been approved by the FDA and are available in oral, topical, and injectable forms. A popular use of hyaluronic acid in recent years is cosmetic injection due to its ability to minimize the appearance of wrinkles and aging-related skin imperfections.

Indication

The intra-articular preparations of hyaluronic acid are indicated for knee pain associated with osteoarthritis. Hyaluronic acid is used in cosmetic applications to prevent and reduce the appearance of wrinkles on the face, and as a dermal filler to correct facial imperfections or other imperfections on other parts of the body. It is frequently an ingredient in topical applications for wound healing and symptomatic treatment of skin irritation from various causes. Hyaluronic acid may also be indicated in ophthalmological preparations or oral capsules to treat discomfort caused by dry eyes or conjunctivitis and for its protective qualities during and before eye surgery. Finally, hyaluronic acid can be used off-label to coat the bladder for relief of interstitial cystitis symptoms.

Associated Conditions
Actinic Keratosis (AK), Burns, Chronic Skin Ulcers, Conjunctivitis, Dehydration, Dermabrasion, Dermatosis, Dry Eyes, Facial Defect, Interstitial Cystitis, Keratoconjunctivitis, Ocular Irritation, Osteoarthritis (OA), Pain of the knee, Seasonal Allergic Conjunctivitis, Skin Burn, Skin Irritation, Skin fissures, Tissue Adhesions, Varicose Ulcers, Wound, Eye discomfort, Facial fine wrinkling, Sensation of burning in the eyes, Superficial Wounds
Associated Therapies
Dermal Filler, Promotion of wound healing, Synovial Fluid Lubrication

The Efficacy Study of Sodium Hyaluronate to Treat Symptomatic Hip Osteoarthritis

Phase 3
Terminated
Conditions
Symptomatic Hip Osteoarthritis
Interventions
Drug: placebo injection
Drug: Sodium hyaluronate
First Posted Date
2006-05-25
Last Posted Date
2008-01-09
Lead Sponsor
Daiichi Sankyo
Target Recruit Count
85
Registration Number
NCT00330135

A Phase I/II Study of Chondrogen Delivered by Intra-Articular Injection Following Meniscectomy

Phase 1
Completed
Conditions
Recovery Following Partial Medial Meniscectomy
Interventions
Drug: Mesenchymal Stem Cells
Drug: Hyaluronan
First Posted Date
2005-09-23
Last Posted Date
2021-12-27
Lead Sponsor
Mesoblast International Sàrl
Target Recruit Count
60
Registration Number
NCT00225095
Locations
🇺🇸

Orthopedic Center of Vero Beach, Vero Beach, Florida, United States

🇺🇸

Ortholndy, Indianapolis, Indiana, United States

🇺🇸

Greater Chesapeake Associates, Baltimore, Maryland, United States

and more 5 locations
© Copyright 2025. All Rights Reserved by MedPath